The AHA today urged the Centers for Medicare & Medicaid Services to consider alternative payment solutions to promote beneficiary access to chimeric antigen receptor T-cell (CAR T) therapy and other new technologies that “offer extraordinary potential to save lives, but are also associated with extraordinary costs.” In a letter to CMS, AHA recommended immediate and longer-term actions to “promote beneficiary access to these therapies, set appropriate precedents for how they are handled in rating setting and preserve opportunities for additional payment options in the future.” On Friday, CMS proposed that Medicare cover CAR T therapies approved by the Food and Drug Administration when they are prescribed by the treating oncologist and performed in a hospital meeting certain criteria.

Related News Articles

Adam Boehler, senior advisor to the Health and Human Services Secretary, Centers for Medicare…
The Medicare Payment Advisory Commission Friday released its March report to Congress.
Sen. Roy Blunt, R-Mo., will speak at the AHA Annual Membership Meeting on April 8 in Washington, D.C.
Chairperson's File
Together, we have a chance to design coordinated systems of support for patients and their families – next-generation care that will build a nation of…
As our country works to expand health coverage and improve access to care, “Medicare for All” is getting a lot of attention. There are many different flavors…
Legislative proposals for a Medicare public option could negatively affect patient access to care and significantly reduce payments to hospitals, AHA Executive…